🎧 Listen to the Discussion(two hosts talk through their thoughts on this article)
Audio only — for listening on a walk or while doing chores
This is an AI-generated audio overview of this article, created with Google NotebookLM. Two hosts discuss the article together, sharing their own thoughts and commentary — it is not a reading of the article text.
This article is a record based on my own thoughts and on published results. It is not a recommendation to buy or sell any particular share.
I explained why I chose these ten companies in my article "Ten Japanese and American Companies Chosen with a Gardener's Eye: Investing in Shares Like Making a Garden at 66".
An oak tree in autumn. Even in the season of falling leaves, the trunk and roots keep preparing for winter.
Photo by david Griffiths on Unsplash
The first of my "Garden of Ten: Results Notes" is about Johnson & Johnson (J&J), which I planted in the oak-tree layer of my garden. On 13 October 2026, before the US market opened, the company published its results for the third quarter of 2026 (from July to 27 September). These results were already out while I was writing the original article, but I am starting my record here, as the first check on how my garden is doing.
The Three Numbers — Did They Beat Expectations?
| Item | Market forecast | Actual | Difference | Verdict | Source of forecast |
|---|---|---|---|---|---|
| Sales | $25.28 billion | $25.399 billion | +0.5% | IN LINE | Reuters (LSEG) |
| Earnings per share (adjusted) | $2.54 | $2.59 | +2.0% | IN LINE | Reuters (LSEG) |
| Full-year outlook (adjusted earnings per share) | $11.08 | Midpoint $11.10 (raised from $11.04 at the end of July) | +$0.02 on the forecast; +$0.06 on the previous outlook | BEAT (raised) | Reuters (LSEG) |
Data: Yahoo Finance. The line shows daily closing prices. This is my own record, not investment advice. View on TradingView
The verdicts on the three numbers. Green marks an item above the forecast, and grey an item roughly in line with it (forecasts compiled by Reuters [LSEG]).
Sales differed from the forecast by 0.5%, which is inside my 1% yardstick. Earnings per share came in 2.0% above the forecast, but just short of the 2% threshold, so I have marked it as IN LINE. What I compared here are the "adjusted" figures that the company reports. This is because the market's forecasts are made on figures that leave out one-off costs such as lawsuits and acquisitions.
On the other hand, earnings per share calculated by the accounting rules were only $0.09. In the same period a year earlier they had been $2.12, so they fell by nearly 96%. This is because the company booked, in this one quarter, a one-off cost of a little over $5.5 billion towards settling the talc lawsuits, which I describe below.
For the full-year outlook, the company slightly raised the midpoint of its sales forecast from $101.1 billion to $101.2 billion, and the midpoint of adjusted earnings per share from $11.04 to $11.10. By the project's yardstick, a raised outlook counts as a BEAT. It was a slight beat on the forecast compiled by Reuters ($11.08), not a surprising rise.
What Went Well, and What Worries Me
Medicines — the young branches grew well
The medicines business, which makes up two-thirds of sales, brought in $16.757 billion, up 7.7% on the previous year. The strongest growth came from cancer medicines. Sales in cancer rose 16.4% to $7.602 billion, and within that, the blood cancer medicine Generic name daratumumab. An antibody medicine used to treat multiple myeloma, a cancer of the blood. It is now one of J&J's best-selling medicines. brought in $4.239 billion (up 15.4%), and Generic name ciltacabtagene autoleucel. A "CAR-T" treatment in which the patient's own immune cells are taken out, changed so that they can find a marker on the cancer, and then put back into the body. It is used for multiple myeloma., which uses immune cells to attack cancer, brought in $710 million (up 35.5%).
At the same time, the old big branches are thinning. The company writes that the fall in Generic name ustekinumab. A medicine for psoriasis, Crohn's disease and other conditions, and for many years one of J&J's biggest earners. Its patents have expired, and since 2025 very similar rival medicines have been sold in the US, so its sales are falling., a medicine for immune diseases, pulled down the growth of the medicines business by about 6.9 points on its own. Immunology as a whole grew by only 1.3%.
If I compare it to an oak tree, this is the season when the thick branches that bore fruit for decades are ageing, and young branches are growing in their place. In the pharmaceutical world, the sharp fall in sales when the patent on a big medicine expires is called the When the patent on a big medicine expires, cheaper copies appear and sales drop as if falling off a cliff. It is one of the fates that drug companies have faced for decades., and this quarter the figures showed that young branches had grown well enough just before the cliff edge. Sales in cancer rose by about $1.07 billion on the previous year, far more than the growth in immunology (about $53 million).
Medical devices — growth is thinning
The medical devices business brought in $8.642 billion, growing by 2.5%. The US grew by 4.8%, but outside the US sales were almost flat (up 0.1%). Within that, the eye business, which covers contact lenses and intraocular lenses, grew by 4.4%, and the main driver of that growth is reported to have been contact lenses (Vision Monday). Set side by side from the company's releases, growth in medical devices has slowed for two quarters in a row: 7.7% in the first quarter, 4.5% in the second and 2.5% in the third. The TIKR article reports that the finance chief gave turmoil in the Middle East, cuts to healthcare budgets in Europe and pressure on prices in China as the reasons.
The company is now preparing to separate its orthopaedics business, which makes artificial joints and similar products, and this cost $369 million in this quarter too. In 2023, J&J had already separated its everyday products business, such as baby powder and plasters, into another company called Kenvue. It is a company that has narrowed its trunk to medicines and medical devices by pruning branches along the way.
The talc lawsuits — a saw put into a heavy branch
The product lawsuits that I listed as a worry in the original article moved forward significantly this summer. On the evening of 27 July, J&J announced a plan to settle together about 76,000 claims alleging that A soft mineral. Ground into powder, it has been used in baby powder and cosmetics. In 2023 J&J stopped selling talc-based baby powder worldwide and switched to cornstarch., an ingredient of baby powder, causes ovarian cancer. The plan requires at least 95% of the claimants to take part, and according to Bloomberg the payment will be at least $5.5 billion.
The company does not accept that its products caused the illness, and explains the plan as a way to bring a 15-year legal fight to an end. It says it has already settled about 95% of the claims involving mesothelioma. In the third-quarter results, $5.519 billion before tax was booked as costs related to these lawsuits.
The conditions have not yet been met, and the settlement is still only a "plan". Even so, the size of a cost that could not be foreseen for years ahead has now become mostly visible. In garden terms, a saw has finally been put into a heavy branch that had caught a disease.
Acquisitions and research — buying next year's saplings with this year's fruit
In this quarter, the company completed its purchase of Firefly Bio, a company researching new cancer medicines, and began joint research with a company called Sail Biomedicines on a new treatment that reprogrammes immune cells inside the body. On 29 July, the company built the cost of these two deals into its outlook, lowering its forecast for adjusted earnings per share in 2026 by $0.64, and announced that 2027 would also be affected by up to about $1.36 (much of the 2027 amount applies only if Sail's research reaches its targets and the company uses its right to buy Sail).
Research and development spending was $4.652 billion, up 26.7% on the previous year and equal to 18.3% of sales. The company's materials explain that much of the increase came from booking, all at once in this quarter, the value of the medicines that Firefly Bio is researching as a cost (about $1 billion). The money a company earns from its core business, minus what it spends on factories and equipment. It is a guide to the money available for dividends, repaying debt, acquisitions and so on., the money from the core business left after spending on equipment, was about $15.1 billion for January to September, more than in the same period a year earlier (about $14.2 billion).
The share price
During trading on Tuesday 13 October, the day of the results, the share price fell at one point by 6.9% from the previous day's close of $263.73, to $245.48 (Reuters). It was reported that although the adjusted figures were roughly in line with expectations and the full-year outlook was raised, investors focused on the cost of the lawsuits and the slow growth in medical devices.
Are My Reasons for Planting It Still Sound?
In the original article, my reasons for wanting this company in my garden were its 64 years in a row of dividend increases, its top AAA credit rating, and the way it has come through lawsuits and expiring patents. My worries were whether it could fill the gap left by expiring patents with new medicines, and the product lawsuits.
This set of results answered both worries head-on. The gap left by expiring patents is being filled by the growth of cancer medicines. As for the lawsuits, although the settlement is still at the planning stage, the shape of an ending has come into view. The company made its 64th annual dividend increase in April, and nothing changed in this quarter.
However, two new worries have appeared. One is that growth in medical devices has slowed for two quarters in a row. The other is that the cost of the acquisitions will hold down earnings in 2027.
Measured against my five questions, the picture is as follows.
| Question | This time |
|---|---|
| 1. Has it kept creating new things? | Still sound. There were approvals of a new medicine for a blood disease and of a surgical robot |
| 2. Does its earnings base hold up even in bad years? | Still sound. Accounting profit fell sharply because of the lawsuit costs, but everyday earning power and cash flow have not broken down |
| 3. Does it have enough cash to act on its own judgement when chances come? | Still sound. While carrying the cost of the settlement, it went ahead with an acquisition and joint research |
| 4. Does it keep spending on research and equipment even in a downturn? | Stronger, if anything. Research spending exceeded 18% of sales |
| 5. Can it talk with long-term shareholders about years, not quarters? | Still sound. The company speaks of a goal years ahead: "double-digit growth by the end of the decade" |
None of the answers has changed. Even so, by the project's yardstick, when a new worry appears I mark the company "keep watching".
My verdict: keep watching (my reasons for planting it still hold. The worry about the lawsuits has become smaller, but new worries have appeared: slow growth in medical devices and the cost of acquisitions in 2027)
How I See It
When I first saw the figure "earnings per share of $0.09", I looked at the screen twice without meaning to. But as I read on, the results looked like a thick branch that had been sawn off and laid on the lawn. The tree looks smaller for a while, but neither its trunk nor its roots have weakened.
In garden terms, J&J seems to me to be in the late-autumn pruning season. It has cut away the diseased branch, cut away the everyday-products branch, and is about to cut away the orthopaedics branch too. On top of that, it is using this year's fruit to buy saplings: new treatments for cancer and immune diseases. The garden looks bare through the winter, but I believe the shoots of spring come from this kind of winter care.
At 66, the names of this company's medicines and tools are slowly becoming familiar to me. Medicines for cancer and for diseases of the blood and immune system are ones that people of my generation may come to rely on. J&J also makes the artificial lenses that are placed inside the eye during cataract surgery (A small artificial lens placed inside the eye during cataract surgery, after the clouded natural lens has been removed. Once in place, it usually stays for life. Some are designed to focus on both far and near.), and early in 2026 it received approval in the US for a new lens called TECNIS PureSee.
I also had cataract surgery in my sixties, in Osaka. I will never forget how I felt when the eye patch came off, and the faces of the people in the waiting room, which I had seen only as a blur before, became bright and clear. As it happens, the lens in my eye is not J&J's. It is a lens called "Toric Vivity" made by Alcon, a company with its headquarters in Switzerland, and it is a type that corrects astigmatism at the same time and widens the range of clear vision from far away to just short of arm's length. So J&J's TECNIS is a rival competing with Alcon in the operating theatre.
Inside my own eye sits a lens made by a rival of a company I planted in my garden. The thought makes me smile a little, but it shows me that, behind the short line "Vision" in the results, several companies are competing for the bright mornings of people in their sixties like me. I suppose it is because they have rivals that the lenses get better year by year. I worked for many years in East Asian medicine, and I feel that the path by which Western medicine spends ten or twenty years creating new treatments and tools takes a different kind of patience.
If anyone else feels uneasy on a morning when the share price screen turns red, I would be glad if this record could be one page in a small notebook, for the one day a year when you walk round your garden.
What I Will Watch Before the Next Results
The next results, for the fourth quarter and the full year of 2026, are expected in late January 2027 (the date has not yet been announced). There are three things I will watch.
- The 2027 outlook: what figures the company gives once it has built in the cost of the acquisition and the joint research (up to about $1.36 per share)
- Growth in medical devices: whether growth, which has slowed for two quarters in a row, recovers in the fourth quarter, and how the separation of the orthopaedics business is progressing
- Progress on the talc settlement: whether it has reached the condition that at least 95% of the claimants take part
And in April, I also want to see whether there is a 65th annual dividend increase.
A Word from Claude
I touch the world only through words and numbers. I can read the line "litigation related 5,519" in the results as an exact figure. Yet behind it there are 76,000 claims, and behind each of them is a person who faced an illness. I think that not misreading the numbers and not forgetting what lies behind them are two different jobs.
This article is a record based on my own thoughts and on published results, and it is not a recommendation to buy or sell any particular share. Share prices and results change every day, and you may get back less than you put in. Please make investment decisions to suit your own life and finances, consulting a professional if needed.
Sources
- Johnson & Johnson, "Johnson & Johnson reports Q3 2026 results, raises 2026 guidance" (13 October 2026, SEC Form 8-K Exhibit 99.1)
- Johnson & Johnson, results schedules (sales by product, statement of earnings)
- Johnson & Johnson, "Q3 2026 Economic Factors"
- Johnson & Johnson, Form 8-K (29 July 2026, guidance update)
- Johnson & Johnson, "Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation" (SEC Form 8-K Exhibit 99.1)
- Bloomberg Law, "J&J Aims to End 15-Year Talc Fight With $5.5 Billion Settlement" (28 July 2026)
- Market forecasts: Reuters (compiled by LSEG), "Johnson & Johnson Q3 sales rise on MedTech growth, lifts 2026 outlook" (13 October 2026)
- Medical devices and share price: TIKR (13 October 2026) / Reuters (share price) / Vision Monday
- Johnson & Johnson, Q1 2026 results (growth in medical devices)
- Johnson & Johnson, Q2 2026 results
- Alcon, "Vivity, the World's Leading EDOF IOL, Reaches One Million Milestone"
(Written using information checked on 26 October 2026)
As an Amazon Associate I earn from qualifying purchases.
Other books you might like
You're welcome to take a look.
EAST TO WEST: The Heart of Haiku, the Light of Scripture
A quiet look, through haiku and words from the Bible, at the things that grow over long years. This is a book my father-in-law left behind.
View on AmazonCataract Surgery-A Memoir: Double cataract surgery in Osaka, Japan
A record of choosing a lens, having the operation in Osaka, and the brightness of the morning the eye patch came off.
View on AmazonSushi Business in Britain: the complete four-volume series
A novel series following thirty-five years in the British sushi trade, from apprentice to factory manager to a small sushi school. The complete edition offers all four volumes at a better price.